A B S T R A C T Dichloroacetate (DCA) markedly reduces circulating cholesterol levels in animals and in patients with combined hyperlipoproteinemia or homozygous familial hypercholesterolemia (FH). To investigate the mechanism of its cholesterol-lowering action, we studied the effects of DCA and its hepatic metabolites, glyoxylate and oxalate, on the activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA reductase) obtained from livers of healthy, reverse light-cycled rats. Oral administration of DCA for 4 d decreased HMG CoA reductase activity 46% at a dose of 50 mg/kg per d, and 82% at a dose of 100 mg/kg per d. A 24% decrease in reductase activity was observed as early as 1 h after a single dose of 50 mg/ kg DCA. The inhibitory effect of the drug was due to a fall in both expressed enzyme activity and the total number of reductase molecules present. DCA also decreased reductase activity when added to suspensions of isolated hepatocytes. With chronic administration, DCA inhibited 3H20 incorporation into cholesterol by 38% and into triglycerides by 52%. When liver microsomes were incubated with DCA, the pattern of inhibition of reductase activity was noncompetitive for both HMG CoA (inhibition constant [Ki] 11.8 mM) and NADPH (K; 11.6 mM). Inhibition by glyoxylate was also noncompetitive for both HMG CoA (K1 1.2 mM) and NADPH (K1 2.7 mM). Oxalate inhibited enzyme activity only at nonsaturating concentrations of NADPH (K, 5.6 mM Department of Medicine, College ylene glycol, all of which can form glyoxylate, also inhibited reductase activity. Using solubilized and 60-fold purified HMG CoA reductase, we found that the inhibitory effect of glyoxylate was reversible. Furthermore, the inhibition by glyoxylate was an effect exerted on the reductase itself, rather than on its regulatory enzymes, reductase kinase and reductase phosphatase. We conclude that the cholesterol-lowering effect of DCA is mediated, at least in part, by inhibition of endogenous cholesterol synthesis. The probable mechanisms are by inhibition of expressed reductase activity by DCA per se and by conversion of DCA to an active metabolite, glyoxylate, which noncompetitively inhibits HMG CoA reductase. These studies thus identify a new class of pharmacological agents that may prove useful in regulating cholesterol synthesis and circulating cholesterol levels in man.
INTRODUCTION
Hypercholesterolemia is a common disorder in man, but current therapy seldom provides satisfactory control. This is particularly so for patients with homozygous or heterozygous familial hypercholesterolemia (FH),' in whom high circulating levels of total and low density lipoprotein (LDL) cholesterol are associated with premature atherosclerosis (1) . A major defect among patients with FH appears to be diminished binding and uptake of LDL by many cells (2) . The consequent decrease in the utilization of LDL cholesterol results in loss of feedback inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA reductase), the rate-limiting enzyme of cholesterol biosynthesis (3) . Overproduction of cholesterol and reduced catabolism of LDL are thus considered to be the principal cause of hypercholesterolemia in this disease (1) .
Pharmacologic intervention for patients with FH has traditionally relied on drugs, such as anionic resins, that enhance intestinal cholesterol excretion (4, 5) , or those, such as nicotinic acid, that impair synthesis of triglyceride-rich precursors of LDL (6) . Recently, however, competitive inhibitors of HMG CoA reductase, such as compactin (7) and mevinolin (8) , have been developed and have been used in preliminary trials for treatment of heterozygous FH (9) (10) (11) . Although these drugs are potent inhibitors of reductase in vitro, the competitive nature of the inhibition leads to a compensatory increase in enzyme synthesis (12) , an effect that could lead to tachyphylaxis with chronic use. In addition, these drugs may not be effective in patients with homozygous FH (9) , in whom high rates of endogenous cholesterol synthesis are thought to occur. There is need, therefore, for an improved treatment of the hypercholesterolemia associated with this disorder.
The pharmacologic and therapeutic effects of dichloroacetate (DCA) have been extensively explored during the past several years. DCA stimulates glucose uptake. and utilization by peripheral tissues (13) (14) (15) and inhibits hepatic gluconeogenesis (16) (17) (18) . It has been used to reduce hyperlactatemia in patients with lactic acidosis (19) . DCA also exerts noteworthy effects on lipid and lipoprotein metabolism. In rats, the drug inhibits fatty acid and ketone body oxidation by peripheral tissues (13, 14) and is reported either to inhibit (20) or to stimulate (21, 22) fatty acid synthesis in liver without altering hepatocellular morphology (21, 23) . In addition, DCA reduces circulating triglyceride and cholesterol concentrations in obese (24) and diabetic (23, 25) animals, but not in healthy animals (24, 25) . In patients with phenotypes Ilb or IV hyperlipoproteinemia, with or without type II diabetes, DCA decreases plasma cholesterol and triglyceride levels (26) . Furthermore, in two patients with homozygous FH who lacked cell surface LDL receptor activity, the drug induced rapid and marked falls in circulating levels of total and LDL cholesterol, without altering high density lipoprotein cholesterol concentrations (27) .
These results prompted us to explore the mechanism of the cholesterol-lowering effects of DCA. Since the drug reduces cholesterol levels in LDL receptor-negative FH patients, we reasoned it might suppress endogenous cholesterol synthesis. We now report that DCA significantly decreases cholesterol synthesis in rat liver by acting as a noncompetitive inhibitor of HMG CoA reductase. It also significantly reduces hepatic triglyceride formation. The inhibitory effect on reductase is probably mediated both by DCA per se and by hepatic conversion of the drug to an active metabolite, glyoxylate, which exerts a noncompetitive, but reversible, inhibition on the enzyme.
METHODS

Materials
Chemicals were from the following sources: DL-3-hydroxy-3-methyl-[3-'4C]glutaric acid (55.1 Ci/mol), [4-14C] 50 and 100 mg/kg were used to reflect therapeutic and supratherapeutic doses used previously in humans (26, 27) . Control rats received only distilled water.
Liver cell isolation and incubation
Isolated, morphologically intact, hepatic parenchymal cells were obtained in high yield by a modification (28) of the technique of Berry and Friend (31) . Livers were perfused in situ with an oxygenated, calcium-free, Krebs-Henseleit original Ringer bicarbonate buffer (pH 7.4) containing 0.05% collagenase. After a 30-45 min perfusion, isolated cells were separated from debris, washed, and resuspended in fresh enzyme-free medium, as previously described (16, 28 
Preparation of microsomal reductase
From hepatocytes. We isolated microsomes by previously described modifications (28, 29) of the method of Shapiro et al. (32) . After incubation, 6 ml of cell suspension was transferred to 10-ml plastic centrifuge tubes and centrifuged at 50 g for 2 min. The supernatant was discarded and replaced with 3.0 ml of a hypotonic medium (buffer A) containing 1.5 mM Tris buffer, 50 mM NaCl, and 18 mM EDTA (pH 7.2). The cells were resuspended, transferred to Dounce homogenizers, and disrupted with 20 strokes of a loose fitting pestle. 7 ml of buffer B, containing 300 mM sucrose, 10 mM beta-mercaptoethanol, 10 mM EDTA, and 50 mM NaCl was added to each tube. The suspension was centrifuged for 10 min at 10,000 g, again for 10 min at 15,000 g to remove mitochondria and associated HMG CoA lyase activity, and finally for 60 min at 100,000 g. The supernatant liquid from the final centrifugation was decanted and the remaining microsomal pellet was frozen in dry ice/acetone and stored at -70°C for up to 3 wk. Before assay of HMG CoA reductase activity, pellets were resuspended in 300 pu of buffer C containing 50 mM imidazole, 50 mM NaCl, 5 mM dithiothreitol, and 1 mM EDTA (pH 7.5).
From whole livers. DCA-treated rats were anesthetized with pentobarbital, their livers were excised and equal portions from three to four animals were pooled. All subsequent operations were performed at 4°C. For the acute or chronic feeding studies, 4-5 g of liver was homogenized in 20 ml of buffer B with a motor-driven Potter-Elvehjem pestle. The homogenate was centrifuged, and the microsomes were isolated, frozen, and stored as described above. For the kinetic studies with microsomal reductase, pooled liver fractions were homogenized in buffer D (40 mM Tris [pH 7.5], 1 mM EDTA, 5 mM dithiothreitol), which also contained 70 mM KCI, with 10 strokes of a loose fitting Dounce pestle followed by 10 strokes of a tight fitting pestle. After centrifuging the homogenate for 10 min at 27,000 g, the precipitate was discarded and the supernatant was centrifuged for 90 min at 105,000 g. The supernatant was removed and the precipitate was suspended in 0.38 ml of buffer D containing 70 mM KCI/g wet wt liver by gentle homogenization with a motor-driven Potter-Elvehjem pestle. The suspension was divided into 2.0-ml portions and frozen in liquid N2.
Preparation of solubilized reductase Microsomal reductase was solubilized and purified 60-fold by the heat fractionation procedure described by Rogers et al. (33) . Microsomes from the livers of 15 rats, killed at the middark period, were washed with 350 ml of buffer D, which also contained 50 mM KCI, and centrifuged at 105,000 g for 90 min. The washed microsomes were frozen overnight in liquid N2. Microsomes were subsequently thawed and incubated in 18 ml of buffer D, containing 50% glycerol, for 1 h at room temperature. The microsomal suspension was diluted to 350 ml with buffer D, containing 1 M KCI, and centrifuged at 105,000 g for 90 min. The microsomal pellet was discarded and the reductase contained in the supernatant was precipitated between 35 and 50% ammonium sulfate saturation. The precipitate was dissolved in buffer D, containing 1 M KC1 and 30% glycerol, heated in a 60°C water bath for exactly 5 min, cooled to room temperature, and centrifuged at 20,000 g for 30 min. The resulting supernatant was retained as solubilized reductase, frozen in liquid N2, and used within 1 wk. Under these conditions, solubilized reductase retains full activity.
Assay of enzyme activity
Assay of microsomal HMG CoA reductase. HMG CoA reductase activity was measured essentially as described by Hunter and Rodwell (34 (35) . ['4C]HMG CoA was omitted from the cofactor-substrate solution and was added directly to the assay mixture at the desired final concentration. Reductase activity was measured in a 2.9-min incubation at 37°C. For determination of the effects of DCA, its analogues or its metabolites on reductase activity, microsomes and drugs were incubated together for either 0 or 20 min at 37°C before measurement of enzyme activity.
Assay of glucose-6-phosphate dehydrogenase. Assays contained, in a final volume of 3 Measurement of 3H20 incorporation into digitonin-precipitable sterols Paired control and DCA-treated rats received an intraperitoneal injection of 5 mCi 3H20 in a volume of 0.2 ml at 8:30 a.m. (30 min before the diurnal peak for reductase ac-tivity). 1 h later, animals were anesthetized with an intraperitoneal injection of pentobarbital. The abdominal cavity was opened and 0.5 ml blood was obtained from the inferior vena cava for determination of 3H20 specific activity, as described by Jeske and Dietschy (36) . Next, a cannula was inserted into the portal vein. The inferior vena cava was cut below the level of the renal veins and the liver was perfused with 60 ml saline (25°C) at a rate of 30 ml/min. The liver was excised and two 2-g portions, comprising equal amounts from the three major lobes, were obtained. The samples were extracted into chloroform/methanol, 2 [36] ).
5 ml of 96% ethanol and 10 ml of 5 M NaOH were added to the dry residue. The mixture was sealed, heated in an 800 C water bath for 3 h, and then cooled to room temperature and stored overnight in the dark. The next day, 20 ml petroleum ether and 20 ml 50% ethanol were added to each sample. Samples were transferred to a 125-ml separatory funnel and mixed for 10 min. The petroleum ether phase, containing nonsaponifiable lipids, was removed. The aqueous phase was washed with two successive 10-ml portions of petroleum ether. The three petroleum ether extracts (40 ml) were washed free of alkali with 50 ml of 50% ethanol. The ethanol wash was added to the original aqueous solution (containing the saponifiable lipids) and was retained for estimation of the rate of triglyceride synthesis. The washed petroleum ether extract was diluted to a volume of 40 ml with petroleum ether, and two 16-ml aliquots were dried under air at 60°C. The dried residues were dissolved in 4 ml of 95% ethanol/acetone, 1:1. The solution was mixed with 2 ml of a 0.5% digitonin solution in 50% ethanol and stored overnight at room temperature in the dark. The next day, the samples were centrifuged for 15 min at 2,400 rpm at 20°C and the supernatant was discarded. The digitonin precipitate was washed with 6 ml diethyl ether/acetone, 1:1 (vol/vol), followed by 12 (cpm 3H/ml plasma)(1.09) (5.56 X 107 nmol H20/ml H20)(0.92 ml H20/ml plasma)
The term 1.09 corrects the specific activity of plasma water, determined at 1 h after 3H20 injection, to the mean specific activity of body water present throughout the 1-h incubation (36) . The 0.92 term corrects the calculation for the percentage of plasma that is water (36, 37) . The rate of triglyceride synthesis by the liver, expressed as micromoles of 3H20 incorporated into triglycerides per gram wet weight of liver per hour, was calculated by dividing the 3H counts per minute measured in the saponifiable lipids fraction by the product of the liver sample weight (in grams), the time of incubation (in hours), and the specific activity of plasma water (3H counts per minute per micromole of H20). The rate of cholesterol synthesis by the liver, expressed as micromoles of 3H20 incorporated into digitonin-precipitable sterols (DPS) per gram wet weight of liver per hour, was calculated as above by dividing the total 3H20 incorporated into DPS by the product of the weight of the liver sample (in grams), the time of incubation (in hours), and the specific activity of the plasma water (3H counts per minute per micromole of water). The total 3H20 incorporated into DPS was calculated by using the following relationship:
Total 3H cpm into DPS = [(3H20 in the digitonin precipitate) -(spill)('4C cpm in the digitonin precipitate)] ( total'4C cholesterol added 14C cpm in the digitonin precipitate)
The spill term represents the fraction of 14C measured as 3H. The (spill) (14C cpm) term corrects the 3H cpm measured in the digitonin precipitate for this spillover. The total [14C]cholesterol added divided by the 14C measured in the digitonin precipitate corrects the calculation both for losses incurred during isolation and for use of only two-fifths of the petroleum ether extracts in determining 3H-labeled digitonin-precipitable sterols.
Reductase activity, expressed as picomoles of mevalonate formed from HMG CoA and NADPH per minute of incubation at 37°C, was calculated as described by Shapiro et al. (32) . (Table II) . In addition, the drug also significantly de- creased (52%, P < 0.01) 3H20 incorporation into hepatic triglycerides.
RESULTS
DCA is not metabolized by muscle tissue of the rat (14) . However, DCA is decarboxylated and oxidized by rat liver to glyoxylate, oxalate, and CO2 (39, 40) .
To determine whether the inhibition of reductase activity by DCA observed in vivo and in isolated cells was due to the drug itself, its metabolites, or both, we studied the effect of DCA, glyoxylate, and oxalate on reductase, using microsomes to which the test drug was added for 20 min at 37°C before addition of the cofactor-substrate solution, or to which the test drug and cofactor-substrate solution were added simultaneously but separately to the microsomes. As shown in Fig. 1 , preincubation of microsomes with glyoxylate led to a dose-dependent decrease in HMG CoA re- In the chronic drug administration studies, rats received water (n = 13), 50 mg/kg DCA (n = 13), or 100 mg/kg DCA (n = 7) once daily for 4 d. Rats were killed at 9:30 a.m. on the 5th d, 24 h after the last orogastric feeding, and the livers from each group were pooled. Equal portions from each pool of livers were homogenized and microsomes were prepared, as described in Methods. In the in vitro experiments, isolated hepatocytes obtained from three rats were divided equally into flasks containing no added DCA or 1.0 mM DCA and incubated at 37°C for 90 min. For both whole liver and hepatocyte studies, HMG CoA reductase activity was assayed in duplicate, as described in Methods. Values are means±SEM. Oxalate had no effect on enzyme activity, regardless of whether the microsomes were fresh or whether a preincubation step was used.
HMG CoA reductase is modulated, in part, by a phosphorylation-dephosphorylation mechanism (41, 42) . Reductase kinase, an ADP-requiring protein kinase (30) , converts HMG CoA reductase into an inactive, phosphorylated form, while a Ca2+-dependent phosphoprotein phosphatase regenerates the active enzyme (40, 41) . In theory, therefore, an agent that stimulates reductase kinase or inhibits reductase phosphatase might indirectly inhibit HMG CoA reductase. To explore these possibilities, microsomes were preincubated with glyoxylate in the presence or absence of sodium fluoride (to inhibit reductase phosphatase), EDTA (to inhibit reductase kinase), or both. As shown in Table III Fig. 3 ). Since irreversible inhibition as well as reversible, noncompetitive inhibition results in similar double reciprocal plots (43) , we examined the reversibility of enzyme inhibition by glyoxylate, using microsomal reductase, solubilized and purified 60-fold. A secondary plot of maximum velocity (Vmax) vs. enzyme concentration revealed the noncompetitive inhibition by glyoxylate was reversible (Fig.  4) . DCA was also a noncompetitive, although less potent, inhibitor of the reductase, (Ki 11.8 mM for HMG CoA and K, 11.6 mM for NADPH). Oxalate was an uncompetitive inhibitor only at nonsaturating concentrations of NADPH (Ki 5.6 mM).
We next asked whether the inhibitory actions of DCA and glyoxylate on reductase were due to a change in expressed (unphosphorylated) enzyme activity, total (unphosphorylated plus phosphorylated) activity, or both. The results presented in Table IV preincubation. Trifluoroacetate and trichloroacetate had no effect on microsomal reductase without preincubation, but stimulated activity 22 arid 12%, respectively, after preincubation.
DISCUSSION
The present data demonstrate that DCA, a potent cholesterol-lowering drug in animals (24, 25) and man (26, 27) , is a noncompetitive inhibitor of HMG CoA reductase obtained from rat liver. The decline in enzyme activity, which occurs both in vivo and in vitro in response to DCA, is paralleled by a suppression of hepatic cholesterolgenesis. In addition, hepatic triglyceride synthesis is also markedly reduced by chronic, oral administration of the drug. The inhibitory effect of DCA on reductase activity appears to be mediated, at least in part, by its hepatic conversion to glyoxylate. This is substantiated by the following observations. (a) The inhibitory constants for DCA are an order of magnitude greater than for glyoxylate, (b) DCA inhibits reductase activity in vitro only when it is incubated with microsomes for a period of time before addition of reductase substrates and cofactors, and (c) only those analogues of DCA that can be metabolized to glyoxylate are inhibitors of reductase activity. Preincubation of microsomes with these drugs is required in order to elicit an inhibitory effect on reductase, presumably to allow for their metabolism to glyoxylate.
Both DCA and glyoxylate are noncompetitive inhibitors of HMG CoA reductase. The pattern of inhibition is reversible with respect to NADPH for glyoxylate and, probably, for DCA. The inhibitory effect of glyoxylate is exerted on reductase itself, since it persists when the regulatory enzymes, reductase kinase and reductase phosphatase are inhibited. Although the acute feeding studies and in vitro experiments indicate that the inhibitory effects of DCA and glyoxylate are due to a fall in expressed enzyme activity, the marked suppression of reductase observed with the chronic feeding experiments and the decrease in total reductase activity observed with acute administration suggest that these drugs also reduce the total number of HMG CoA reductase molecules present. Such a change may be due to a decreased rate of enzyme synthesis, an enhanced rate of enzyme degradation, or both. The marked fall in the amount of active reductase present after acute DCA administration, compared with the modest change seen after glyoxylate treatment, suggests Although competitive inhibitors of HMG CoA reductase appear to be effective in reducing hypercholesterolemia in man (9) (10) (11) , the nature of the inhibition leads to a marked increase in intracellular concentrations of reductase molecules (12) . This effect has a theoretical disadvantage in that progressively higher doses of the inhibitor may be required to overcome the increase in reductase synthesis and prevent the development of tachyphylaxis. Indeed, in states in which HMG CoA reductase activity is already markedly elevated, such as in homozygous FH, competitive inhibitors of the enzyme do not appear to be clinically effective (9) . On the other hand, noncompetitive, but reversible, inhibitors of reductase may not lead to an increase in enzyme synthesis and thus may retain their efficacy with chronic use. Furthermore, noncompetitive inhibitors may also be effective in reducing cholesterol synthesis and circulating cholesterol levels in patients with homozygous FH. This premise is substantiated by the observation that chronic administration of DCA leads to marked and sustained decreases in serum total and LDL cholesterol concentrations in two receptornegative homozygous FH patients (27) , one of whom was found subsequently to have an elevated rate of cholesterol synthesis (46) . DCA is not without potential toxicity. One patient who received the drug for -4 mo developed a polyneuropathy that resolved after treatment stopped (27) . Chronic administration of DCA to animals in doses far exceeding those used clinically also induces a reversible peripheral neuropathy (47) (48) (49) . Oxalate, an end product of DCA metabolism (39, 40) , is a known neurotoxin (50, 51) and may be responsible for the neuropathic changes associated with DCA. The clinical efficacy of the drug at doses lower than that causing neurotoxicity, however, has not been tested. Our finding that DCA and glyoxylate represent a new pharmacologic class of potent, noncompetitive inhibitors of HMG CoA reductase suggests that analogues or derivatives of these agents, possessing similar effects on cholesterol and triglyceride metabolism but devoid of serious toxicity, may be important adjuncts in the treatment of hypercholesterolemia and other lipoprotein disorders in man.
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